TABLE 4.

TRAEs according to category and grade

	Total		PD‐1 inhibitors		Antiangiogenic agents
	Any grade	Grade ≥3	Any grade	Grade ≥3	Any grade	Grade ≥3
TRAE	125 (91.9)	38 (27.9)	97 (71.3)	25 (18.4)	115 (84.6)	17 (12.5)
Specific TRAE
Hypertransaminases	45 (33.1)	3 (2.2)	40 (29.4)	3 (2.2)	5 (3.7)	0
Thrombocytopenia	26 (19.1)	6 (4.4)	24 (17.6)	5 (3.7)	2 (1.5)	1 (0.7)
Hypertension	25 (18.4)	2 (1.5)	0	0	25 (18.4)	2 (1.5)
Leukopenia	25 (18.4)	5 (3.7)	25 (18.4)	5 (3.7)	0	0
Hyperbilirubinemia	24 (17.6)	8 (5.9)	21 (15.4)	7 (5.1)	6 (4.4)	1 (0.7)
Loss of appetite	21 (15.4)	0	21 (15.4)	0	21 (15.4)	0
Rash	19 (14.0)	2 (1.5)	14 (10.3)	2 (1.5)	5 (3.7)	0
Hypothyroidism	18 (13.2)	1	18 (13.2)	1 (0.7)	0	0
Anemia	17 (12.5)	0	17 (12.5)	0	0	0
Fatigue	16 (11.8)	0	16 (11.8)	0	16 (11.8)	0
Hand‐foot syndrome	15 (11.0)	4 (2.9)	0	0	15 (11.0)	4 (2.9)
Abdominal bloating	13 (9.6)	0	0	0	13 (9.6)	0
Proteinuria	12 (8.8)	2 (1.5)	0	0	12 (8.8)	2 (1.5)
Diarrhea	11 (8.1)	0	0	0	11 (8.1)	0
Gastrointestinal bleeding	9 (6.6)	7 (5.1)	0	0	9 (6.6)	7 (5.1)
Nausea/vomiting	10 (7.4)	1 (0.7)	0	0	10 (7.4)	1 (0.7)
Pruritus	5 (3.7)	0	5 (3.7)	0	0	0
Lymphopenia	3 (2.2)	0	3 (2.2)	0	0	0
Interstitial pneumonia	3 (2.2)	0	3 (2.2)	0	0	0
Hypophysitis	2 (1.5)	1 (0.7)	2 (1.5)	1 (0.7)	0	0
Hyperthyroidism	2 (1.5)	0	2 (1.5)	0	0	0
Oral mucositis	2 (1.5)	1 (0.7)	0	0	2 (1.5)	1 (0.7)
Elevated creatinine	2 (1.5)	0	0	0	2 (1.5)	0
Hemangioma	1 (0.7)	0	1 (0.7)	0	0	0
Thyroiditis	1 (0.7)	1 (0.7)	1 (0.7)	1 (0.7)	0	0

Note: Data presented as n (%).

Abbreviations: PD‐1, programmed death 1; TRAEs, treatment‐related adverse events.